Resources from the same session
2908 - ARCTIC: durvalumab + tremelimumab and durvalumab monotherapy vs SoC in _3L advanced NSCLC treatment
Presenter: David Planchard
Session: Proffered paper session- NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
2887 - IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase 3 study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC
Presenter: Federico Cappuzzo
Session: Proffered paper session- NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
4038 - IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC)
Presenter: Fabrice Barlesi
Session: Proffered paper session- NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
4485 - Primary efficacy results from B-F1RST, a prospective Phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
Presenter: Edward Kim
Session: Proffered paper session- NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
3420 - Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase 3 trial
Presenter: Elisabeth Quoix
Session: Proffered paper session- NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
Proffered paper session- NSCLC, metastatic - Invited Discussant 1378O and LBA56
Presenter: Naiyer Rizvi
Session: Proffered paper session- NSCLC, metastatic
Resources:
Slides
Webcast